First-in-human study of im156, a novel potent biguanide oxidative phosphorylation (oxphos) inhibitor, in patients with advanced solid tumors

HIGHLIGHTS

• who: Filip Janku from the The University of Texas MD Anderson Cancer Center, Houston, TX, USA have published the Article: First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors, in the Journal: (JOURNAL)
• what: The study was approved by each Institutional Review Board and patients provided written informed consent. The study demonstrated that IM156 is tolerable at RP2D of 800 mg QD.
• how: The authors designed a first-in-human dose-escalation study to determine the maximum tolerated dose (MTD) or recommended . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.